Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
GLP-1 receptor activation does the heavy lifting for appetite suppression
When a cardiovascular event occurs in someone taking weight loss medication, it may reflect their pre-existing risk profile rather than a medication effect
This two-pronged approach addresses both appetite and metabolic efficiency
BPC-157 is a stable gastric pentadecapeptide originally derived from human gastric juice, KPV is a tripeptide fragment of -MSH, PEA (palmitoylethanolamide) is a naturally occurring fatty acid amide, and Tributyrin is a prodrug of butyric acid
CORXEL Pharmaceuticals has raised $287 million in a Series D1 financing to advance its lead obesity program, an oral GLP-1 drug (CX11) that the company has positioned as comparable to injectable weight-loss therapies
